CARDIOVASCULAR RISK MANAGEMENT WITH HORMONE REPLACEMENT THERAPY FOR MENOPAUSE AND MALE HYPOGONADISM / GESTION DU RISQUE CARDIOVASCULAIRE DANS L'HORMONOTHÉRAPIE LORS D'UNE MÉNOPAUSE OU D'UN HYPOGONADISME MASCULIN (CSEM-007)

Disclosure(s):

Beth L. Abramson, MD MSc FRCPC FACC: abbott: Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Biosyent: Speaker/Honoraria (Ongoing); BMS-Pfizer: Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); CHRC: Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Jansen: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Servier: Speaker/Honoraria (Ongoing)

Justin Morein, MDCM, FRCPC: No financial relationships to disclose

Laurie Mereu, MD, FRCPC: No relevant disclosure to display